Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01188304 · ClinicalTrials.gov registry record · Phase 1

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

A Phase 1 study of Healthy Volunteer, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
1
Study location

NCT01188304 is a Phase 1 study of Healthy Volunteer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 44 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01188304, a Phase 1 study of Healthy Volunteer, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with aspirin on renal function, renin-angiotensin system and platelet aggregation in healthy volunteers. Volunteers will be randomized to receive daily doses of aleglitazar or placebo in combination with aspirin. The anticipated time on study drug is 5 weeks.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG aspirin
  • DRUG aleglitazar

Study Locations (1)

Texas

  • - San Antonio

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2010-07
Est. Completion 2010-10
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

What the Registry Record Tells You About NCT01188304

The ClinicalTrials.gov registry entry for NCT01188304 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (78% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT01188304 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01188304 about?

NCT01188304 is a clinical study titled "A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers". This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with aspirin on renal function, renin-angiotensin system and platelet aggregation in healthy volunteers. Volunteers will be randomized to...

What is the current status of trial NCT01188304?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2010-07. Estimated completion is 2010-10.

What conditions does trial NCT01188304 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT01188304?

The interventions under investigation include: placebo (DRUG), aspirin (DRUG), aleglitazar (DRUG).

Who is sponsoring clinical trial NCT01188304?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01188304 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.